{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137043631007872.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s12072-011-9280-0"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s12072-011-9280-0.pdf"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/article/10.1007/s12072-011-9280-0/fulltext.html"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s12072-011-9280-0"}}],"dc:title":[{"@value":"Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137043631007874","@type":"Researcher","foaf:name":[{"@value":"Teerha Piratvisuth"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043631007876","@type":"Researcher","foaf:name":[{"@value":"Patrick Marcellin"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043631007877","@type":"Researcher","foaf:name":[{"@value":"Matei Popescu"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043631007875","@type":"Researcher","foaf:name":[{"@value":"Hans-Peter Kapprell"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043631007873","@type":"Researcher","foaf:name":[{"@value":"Vivien Rothe"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137043631007872","@type":"Researcher","foaf:name":[{"@value":"Zhi-Meng Lu"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"19360533"},{"@type":"EISSN","@value":"19360541"}],"prism:publicationName":[{"@value":"Hepatology International"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2011-06-24","prism:volume":"7","prism:number":"2","prism:startingPage":"429","prism:endingPage":"436"},"reviewed":"false","dc:rights":["http://www.springer.com/tdm"],"url":[{"@id":"http://link.springer.com/content/pdf/10.1007/s12072-011-9280-0.pdf"},{"@id":"http://link.springer.com/article/10.1007/s12072-011-9280-0/fulltext.html"},{"@id":"http://link.springer.com/content/pdf/10.1007/s12072-011-9280-0"}],"createdAt":"2011-06-23","modifiedAt":"2019-06-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004235794584192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B surface antigen reduction by switching from long‐term nucleoside/nucleotide analogue administration to pegylated interferon"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013168850745216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Use of a Deep Learning Approach for the Sensitive Prediction of Hepatitis B Surface Antigen Levels in Inactive Carrier Patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283693322536960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum hepatitis B core‐related antigen as a treatment predictor of pegylated interferon in patients with <scp>HB</scp>eAg‐positive chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204795197696","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of chronic hepatitis B which achieved hepatitis B surface antigen seroclearance during combination therapy with peginterferon alfa-2b and entecavir"},{"@language":"ja","@value":"エンテカビル・ペグインターフェロンα－２ｂ併用４８週治療にてＨＢｓ抗原が消失したＢ型慢性肝炎の１例"},{"@value":"症例報告 エンテカビル・ペグインターフェロンα-2b併用48週治療にてHBs抗原が消失したB型慢性肝炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク エンテカビル ・ ペグインターフェロンa-2b ヘイヨウ 48シュウ チリョウ ニテ HBs コウゲン ガ ショウシツ シタ Bガタ マンセイ カンエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390006895523803776","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Peg-IFNα-2a Contributed to HBs Antigen Seroclearance in a Patient with Chronic Hepatitis B Administered Nucleic Acid Analogs: A Three-year Follow-up"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679772059264","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Comparison of each HBs antigen assay and it's clinical utility"},{"@language":"ja","@value":"HBs抗原の測定法と臨床的意義"},{"@language":"ja-Kana","@value":"HBs コウゲン ノ ソクテイホウ ト リンショウテキ イギ"},{"@value":"Comparison of each HBs antigen assay and it^|^apos;s clinical utility"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s12072-011-9280-0"},{"@type":"CROSSREF","@value":"10.1111/jvh.12691_references_DOI_BWa23nxcrsLF1C6R5ZEP7hsKT8A"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.42_references_DOI_BWa23nxcrsLF1C6R5ZEP7hsKT8A"},{"@type":"CROSSREF","@value":"10.3390/jcm11020387_references_DOI_BWa23nxcrsLF1C6R5ZEP7hsKT8A"},{"@type":"CROSSREF","@value":"10.1111/liv.13046_references_DOI_BWa23nxcrsLF1C6R5ZEP7hsKT8A"},{"@type":"CROSSREF","@value":"10.2957/kanzo.55.310_references_DOI_BWa23nxcrsLF1C6R5ZEP7hsKT8A"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_BWa23nxcrsLF1C6R5ZEP7hsKT8A"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_BWa23nxcrsLF1C6R5ZEP7hsKT8A"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.5783-20_references_DOI_BWa23nxcrsLF1C6R5ZEP7hsKT8A"}]}